Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Vaccinations01:51

Vaccinations

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GLP-1 receptor agonist use and overall survival among women with type 2 diabetes and breast cancer: a retrospective cohort study.

The oncologist·2026
Same author

Multi-state modeling associates proliferation genes with early estrogen receptor-positive breast cancer recurrence and survival.

Research square·2026
Same author

Baseline gene expression and dynamic endocrine therapy use in ER+ breast cancer: associations with recurrence in a real-world cohort.

Research square·2026
Same author

Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: a multi-institution study.

Breast cancer research and treatment·2026
Same author

Characterization of the somatic landscape and transcriptional profile of breast tumors from 748 Hispanic/Latina women in California.

medRxiv : the preprint server for health sciences·2026
Same author

GLP-1 Targeting Agents Impair Chemoimmunotherapy Effectiveness in Triple-Negative Breast Cancer.

Research square·2026

Related Experiment Video

Updated: May 18, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Lessons learned from the bevacizumab experience.

Joanne Mortimer1, Helene B Zonder, Sumanta K Pal

  • 1Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. jmortimer@coh.org

Cancer Control : Journal of the Moffitt Cancer Center
|October 6, 2012
PubMed
Summary

Bevacizumab is an effective cancer drug approved for several solid tumors. Understanding its side effects is key to optimizing its use and identifying patients who will benefit most.

More Related Videos

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Related Experiment Videos

Last Updated: May 18, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Bevacizumab is a key therapeutic agent in oncology.
  • It demonstrates efficacy across a wide range of solid tumors.
  • Approved indications include metastatic colorectal cancer, non-small cell lung cancer, renal cancers, and recurrent glioblastoma.

Purpose of the Study:

  • To review the literature and FDA data regarding bevacizumab's approval status.
  • To understand the drug's mechanism of action and identify patient populations likely to benefit.
  • To analyze the role of treatment-related toxicities in understanding drug efficacy.

Main Methods:

  • Comprehensive review of published scientific literature.
  • Analysis of US Food and Drug Administration (FDA) briefing documents.
  • Examination of clinical trial data supporting drug approval and changes in status.

Main Results:

  • Bevacizumab initially received accelerated approval for advanced breast cancer but later lost this indication due to insufficient confirmatory data.
  • Clinical trials have elucidated both expected and unexpected toxicities associated with bevacizumab.
  • Toxicity profiles offer insights into the drug's mechanism and patient selection.

Conclusions:

  • Treatment-related side effects provide valuable information regarding drug mechanism and efficacy.
  • Bevacizumab is a significant agent in cancer treatment.
  • Future advancements may involve identifying predictive biomarkers for bevacizumab efficacy.